Mylan Inc. is buying Abbott Laboratories’ generic-drug business and forming a new company that will be incorporated in the Netherlands, giving the new operation a lower-cost tax base.

Abbott will get 21 percent of the new organization, valued at about $5.3 billion, the Abbott Park, Illinois-based company said today in a statement. Setting up the company in the Netherlands will drop Mylan’s tax rate below 21 percent in the first year, subsequently declining to the high teens. The company will be run by Mylan’s current executive team from Pittsburgh, where Mylan’s headquarters are now located.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.